Ground-breaking research from Heriot-Watt University and the University of Texas Medical Branch is set to be commercialised following a funding award from Scottish Enterprise’s High Growth Spinout Programme.
The funding, awarded to researchers at Heriot-Watt University, is the first step towards establishing a specialist Scottish biotechnology company to develop treatments for chronic inflammatory diseases and fibrosis.
Inflammation is the body’s normal healing response to damaging stimuli, including infections, injuries, and toxins. However, chronic inflammation happens when the body’s response doesn’t properly resolve, leaving the body in a constant state of alert.
If left untreated, chronic inflammatory disease can lead to serious consequences and it has been calculated that three in every five people die as a result of one of these diseases.
Examples include respiratory, cardiac, vascular, Covid-19 and related viral diseases. Due to the complex nature of inflammatory processes, these diseases are extremely difficult to treat, resulting in continual demand for new medications.
The new research has identified a way of targeting an enzyme called EPAC1, which is involved in the inflammation process and is responsible for many of the most serious yet common chronic diseases.
Dr Stephen Yarwood from the Institute of Biological Chemistry, Biophysics and Bioengineering at Heriot-Watt University explains: “By activating our newly identified enzyme, we can essentially ‘switch off’ inflammation.
“By doing so, we believe we can stop the harm chronic inflammation can do and hope to improve outcomes for patients when these treatments come to market.”
- Robinhood data breach leaks details of 7m customers
- Stagecoach and SSE announce new electric charging hub initiative
- 7 things to know about the Apple-1 computer
The team has already developed several potential new treatment options that show effectiveness in tackling inflammation at its source. Once they reach the market, these medications are expected to offer advantages over existing medications in both efficacy and safety.
Victoria Carmichael, Director of Strategic Investments at Scottish Enterprise, said: “Our High Growth Spinout Programme was established specifically to help commercialise ground-breaking research conducted by Scotland’s universities.
“The development of EPAC1 has the potential to alleviate the suffering caused to millions of people around the world and highlights the important innovation-led approach the country’s academic institutions continue to apply to the management of chronic diseases.”
The funding will be used for further development of the treatments and has also allowed the team to recruit commercial expertise from industry veteran Chris Wardhaugh who will act as a CEO-Designate for the project. The team, which includes Dr Graeme Barker, are working closely with the University’s Global Research Innovation and Discovery (GRID) facility.
Get the latest news from DIGIT direct to your inbox
Our newsletter covers the latest technology and IT news from Scotland and beyond, as well as in-depth features and exclusive interviews with leading figures and rising stars.
We’ll keep you up to date on the pivotal issues impacting the sector and let you know about key upcoming events to ensure that you don’t miss out on what’s going on across the Scottish tech community.
Click here to subscribe.